Amphastar Pharmaceuticals Market Cap 2012-2026 | AMPH

Amphastar Pharmaceuticals market cap history and chart from 2012 to 2026. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Amphastar Pharmaceuticals market cap as of September 17, 2026 is $1.02B.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.019B $0.720B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $44.899B 17.67
BridgeBio Pharma (BBIO) United States $13.352B 0.00
Dr Reddy's Laboratories (RDY) India $9.749B 24.85
Aspen Pharmacare (APNHY) South Africa $4.248B 0.00
Supernus Pharmaceuticals (SUPN) United States $2.409B 20.18
Bausch Health Cos (BHC) Canada $2.129B 1.33
Personalis (PSNL) United States $1.687B 0.00
Taysha Gene Therapies (TSHA) United States $1.652B 0.00
Assembly Biosciences (ASMB) United States $0.519B 24.98
Sol-Gel Technologies (SLGL) Israel $0.178B 0.00
Metagenomi Therapeutics (MGX) United States $0.043B 0.00
Evoke Pharma (EVOK) United States $0.019B 0.00
Teligent (TLGT) United States $0.000B 0.00